Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. is projecting a robust fourth-quarter net revenue between $115 million and $135 million, with an increase in full-year 2025 pro forma net revenue guidance raised to $390 million to $410 million, driven by accelerated adoption of its product, DefenCath. Additionally, the company anticipates fully synergized pro forma adjusted EBITDA to reach between $220 million and $240 million, reflecting strong financial performance and operational efficiency. The positive outlook is further supported by higher-than-expected utilization rates among outpatient dialysis customers and the upcoming potential catalyst from top-line data expected in 2Q26 related to Rezzayo.

Bears say

Cormedix Inc is positioned to capitalize on a significant market opportunity with Niyadas, estimated between $100 million to $200 million, which could enhance its EBITDA due to high gross margins. However, the company faces notable challenges from the uncertainty surrounding the TDAPA pricing headwind, which may negatively impact revenue performance. This combination of potential market opportunity and existing pricing pressures contributes to an overall negative outlook for Cormedix's stock in the near term, despite some anticipated tailwinds in the longer term.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.